An Early Phase 1 interventional study of FMT capsules and Placebo capsules in Aging and Frailty, sponsored by Chinese Academy of Medical Sciences, Fuwai Hospital. Recruiting at 6 sites in China. Open to participants aged 70 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-31.
Sponsored by Chinese Academy of Medical Sciences, Fuwai Hospital · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in Frailty with a site in China — 26 open to participants now, 28 under way, none of them phase 3. Frailty · China.
Among the 65 studies in Frailty with a site in China, this one is the 10th largest by planned enrollment of the 32 interventional ones that give a count, is one of 9 that started in 2023, is one of 2 in phase 1, reaches primary completion later than 13 of the 27 other live ones, and was the 22nd registered.
1,291 studies on the registry are indexed under Frailty; 454 are open to participants now.
Browse Frailty studies →26 of the 65 studies in Frailty with a site in China are open now. Recruiting first, the newest first:
Guangdong Provincial People's Hospital · Sites in China
Ages 75+
Jiawei Jiang · Sites in China
Ages 60–85
Huashan Hospital · Sites in China
Ages 61+
First Affiliated Hospital of Fujian Medical University · Sites in China
Ages 18+ · Healthy volunteers
Lanyue Zhu · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 299 Frailty studies recruiting now, 235 (79%) set no upper age limit and 10 (3%) stop at 75 or younger; 7 take children under 18; 66 take healthy volunteers.
This study: 70 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 2 · Phase 3 1 · Phase 4 2
First in 2013; this study’s year is marked. 9 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 210 is above the median of 83 across 772 interventional studies indexed under Frailty.
Median enrollment 146 across the 32 interventional studies, 500 across the 33 observational. Of the 27 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 65 has an industry lead sponsor. The 10 most frequent:
Chinese Academy of Medical Sciences, Fuwai Hospital is the lead sponsor of 147 studies on the registry; 51 are open to participants now.
Chinese Academy of Medical Sciences, Fuwai Hospital has 1 study filed under Frailty — fewer than ten, so there is no comparison to draw.
8 of the studies in Frailty with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05635877Yongtao SunEffects of Low-dose Esmolol on Myocardial Injury After Non-cardiac Surgery in Elderly Frail Patients | 2026-11-30 |
| NCT06765499First People's Hospital of HangzhouThe Study Evaluating the Improvement of Nutritional Status and Frailty With Silkworm Pupa Powder Among Patients With Motor Neuron Disease | 2026-12-30 |
| NCT07845656Jiawei JiangA Home-based Multicomponent Exercise Intervention Program Based on the Fogg Behavior Model (FBM) for Older Adults With Osteosarcopenia and Frailty | 2026-12-31 |
| NCT07030179Lanyue ZhuThe Relationship Between Preoperative Frailty and Postoperative AKI and the Mediating Effect of Intraoperative BP | 2026-12-31 |
| NCT05598112Chinese Academy of Medical Sciences, Fuwai HospitalEffect of Gut Microbiome Intervention on Aging Via Oral FMT | 2026-12-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 65 studies in Frailty with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A severe public health issue facing global population is aging. Increasing preclinical and clinical data indicate the contribution of gut microbiome on aging and aging-related diseases such as cardiovascular disease, Alzheimer Disease, and diabetes. Interventions on microbiota are developed including prebiotics, probiotics, and fecal microbial transplantation (FMT). FMT via oral capsules also advances in recent with limited safety concerns compared with invasive routes. A hypothesis is thus raised that gut microbiome intervention via oral FMT can be a potential safe approach to encourage healthy aging, with multiple aspects evaluated for clinical phenotype of frailty, anthropometric measurement, cognitive function, cardiovascular aging, physical function, living activity, hippocampal volume, telomere length, cognitive biomarkers, inflammatory biomarkers, altered microbial composition and metabolites.
Objective: To explore the effect, safety and underlying mechanisms of gut microbiome intervention via FMT on aging. Study Design: A multi-center, randomized, blinded, placebo-controlled pilot study. Data quality control and statistical analysis: The investigators have invited professional statistic analysts to assist analyzing data and a third party to supervise data quality. Ethics: The Ethics Committee of Fuwai Hospital approved this study. Informed consents before patient enrollment are required.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FMT capsules containing extensively screened donor stool. FMT capsules will be orally taken on week 0, week 4, week 8, week 12, week 24, week 28, week 32, week 36, week 48, week 52, week 56, week 60, week 72, week 76, week 80, week 84.
Biological: FMT capsules
Placebo capsules that do not contain donor stool or any active drug. Placebo capsules will be orally taken on week 0, week 4, week 8, week 12, week 24, week 28, week 32, week 36, week 48, week 52, week 56, week 60, week 72, week 76, week 80, week 84.
Other: Placebo capsules
FMT capsules containing extensively screened donor stool.
Placebo capsules that do not contain donor stool or any active drug.
Proportion of participants with reduced frailty score at week 96 follow-up
Frailty score via CHS criteria of five frailty components, compared with baseline
Time frame: week 96
Proportion of participants with reduced frailty score at week 12 follow-up
Frailty score via CHS criteria of five frailty components, compared with baseline
Time frame: week 12
Proportion of participants with reduced frailty score at week 24 follow-up
Frailty score via CHS criteria of five frailty components, compared with baseline
Time frame: week 24
Proportion of participants with reduced frailty score at week 48 follow-up
Frailty score via CHS criteria of five frailty components, compared with baseline
Time frame: week 48
Proportion of participants with reduced frailty score at week 72 follow-up
Frailty score via CHS criteria of five frailty components, compared with baseline
Time frame: week 72
Change from baseline in Frailty score
Frailty score via CHS criteria of five frailty components, ranging from 0 to 5, with higher score indicating worse outcome
Time frame: week 12, week 24, week 48, week 72, week 96, compared with baseline
Change from baseline in telomere length
Change from baseline in telomere length
Time frame: week 48, week 96
Change from baseline in Cognitive assessment via Mini Mental State Examination(MMSE)
MMSE (Mini Mental State Examination) ranging from 0 to 30, with lower score indicating worse outcome
Time frame: week 24, week 48, week 72, week 96, compared with baseline
Change from baseline in Cognitive assessment via Montreal Cognitive Assessment(MoCA)
MoCA (Montreal Cognitive Assessment) ranging from 0 to 30, with lower score indicating worse outcome
Time frame: week 24, week 48, week 72, week 96, compared with baseline
Change from baseline in Hippocampal volumes
Hippocampal volumes evaluated by Magnet Resonance Imaging
Time frame: week 48, week 96
Change from baseline in cognitive biomarkers
plasma levels of cognitive biomarkers for BDNF、tau、Aβ-40、Aβ42
Time frame: week 12, week 24, week 48, week 72, week 96
Change from baseline in inflammatory biomarkers
plasma levels of inflammatory biomarkers for hs-C-reactive protein (hs-CRP)、 interleukin 6(IL-6)、interleukin 1 β(IL-1 β) 、interleukin10 (IL-10)、tumor necrosis factor α(TNF-α)
Time frame: week 12, week 24, week 48, week 72, week 96
Change from baseline in Intestinal Microbiota Composition Pre- and Post-intervention via Metagenomic Analysis
Change in Intestinal Microbiota Composition Pre- and Post-intervention (FMT or Placebo) via Metagenomic Analysis, stratified by: 1. Randomisation 2. Change in Office SBP
Time frame: week 12, week 24, week 48, week 72, week 96
Change from baseline in Intestinal Microbiota Function assessed by KEGG Orthology (KO) Pre- and Post-intervention via Metagenomic Analysis
Change in Intestinal Microbiota Function assessed by KEGG Orthology (KO) Pre- and Post-intervention (FMT or Placebo) via Metagenomic Analysis, stratified by: 1. Randomisation 2. Change in Office SBP
Time frame: week 12, week 24, week 48, week 72, week 96
Change from baseline in Plasma Metabolite Composition Pre- and Post-intervention via Metabolomic Analysis
Change in Plasma Metabolite Composition Pre-and Post-intervention (FMT or Placebo) via Metabolomic Analysis
Time frame: week 12, week 24, week 48, week 72, week 96
Change from baseline in Ankle-Brachial Blood Pressure Index(ABI)
Change for ABI as an objective measurement of arterial insufficiency based on the ratio of ankle systolic pressure to brachial systolic pressure.
Time frame: week 48, week 96
Change from baseline in Pulse wave velocity(PWV)
Change for Pulse wave velocity(PWV)
Time frame: week 48, week 96
Number of Participants with Adverse Events (AEs) as a Measure of Safety
Number of Participants with Adverse Events (AEs) as a Measure of Safety
Time frame: week 12, week 24, week 48, week 72, week 96
Change from baseline in Body Mass Index (BMI)
Change for Body Mass Index
Time frame: week 4, week 8, week 12, week 24, week 48, week 72, week 96
Change from baseline in office SBP
change for office systolic blood pressure(SBP)
Time frame: week 4, week 8, week 12, week 24, week 48, week 72, week 96
Change from baseline in office DBP
change for office diastolic blood pressure(DBP)
Time frame: week 4, week 8, week 12, week 24, week 48, week 72, week 96
Change from baseline in Blood Lipid Level
Change for Blood Lipid Level (Total Cholesterol, Total Triglyceride, Low Density Lipoprotein Cholesterol, High Density Lipoprotein Cholesterol)
Time frame: week 12, week 24, week 48, week 96
Change from baseline in blood fasting glucose level
Change for blood fasting glucose level
Time frame: week 12, week 24, week 48, week 96
Change from baseline in blood HbA1c level
Change for blood glycosylated hemoglobin, type A1C (HbA1c) level
Time frame: week 12, week 24, week 48, week 96
Change from baseline in physical function assessment via 6MWT
6-minute walking test(6MWT)
Time frame: week 12, week 24, week 48, week 72, week 96
Change from baseline in daily function assessment via Activity of Daily Living (ADL)
Activity of Daily Living (ADL) ranging from 0 to 100, with lower score indicating worse outcome
Time frame: week 12, week 24, week 48, week 72, week 96
Plan to share: Yes — The collected data, study protocol, and SAP are planned to be shared after the study ends 3 years later (anticipated)
Supporting information: Study protocol, Statistical analysis plan
Time frame: after the study ends 3 years later (anticipated)
Access criteria: Access to these deidentified data will be required for written permission from the responsible investigation center and only for qualified researchers.
Started Apr 2023 (actual). Primary completion is estimated for Dec 2026, 44 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fecal microbiota
Chinese Academy of Medical Sciences, Fuwai Hospital →